

**Analytica Ltd**  
ABN 12 006 464 866

**Appendix 4D**

**Half Year Report**

**For the 6 months ended December 2014 (current period)  
And the previous corresponding period 6 months ended 31 December 2013**

**Results for announcement to the market**

Revenue from ordinary activities:	Up	191%	to	\$1,012,612
(Loss) from ordinary activities after tax attributable to members:	Up	140%	to	(1,923,938)
Net (Loss) for the period attributable to members:	Up	140%	to	(1,923,938)
		Current period		Previous corresponding period
Net tangible asset backing per ordinary share		0.39 cents		1.46 cents
Basic earnings/(loss) per share		(0.2) cents		(0.2) cents

An explanation of the result of the current period is set out in the Directors Report contained in the attached audit reviewed half-year Financial Report

Full financial details of the Company are also contained in the attached audit reviewed half-year Financial Report

Dividends: It is not proposed that any dividend will be paid. No dividends were paid in the previous corresponding period.

# **Analytica Limited**

**ABN: 12 006 464 866**

**Interim Financial Statements**

**For the Half Year Ended 31 December, 2014**

**Analytica Limited**

**Contents**

**For the Half Year Ended 31 December, 2014**

	<b>Page</b>
<b>Interim Financial Statements</b>	
Directors' Report	1
Auditors Independence Declaration under Section 307C of the Corporations Act 2001	4
Interim Statement of Profit or Loss and Other Comprehensive Income	5
Interim Statement of Financial Position	6
Interim Statement of Changes in Equity	7
Interim Statement of Cash Flows	8
Summary of Significant Accounting Policies	9
Notes to the Financial Statements	11
Directors' Declaration	16
Independent Auditor's Review Report	17

## Analytica Limited

# Directors' Report

31 December, 2014

The directors submit the interim financial report of the Company for the half year ended 31 December, 2014.

### 1. General information

#### Information on directors

The names of each person who has been a director during the half year and to the date of this report are:

Dr Michael Monsour

Mr Ross Mangelsdorf

Mr Warren Brooks

Mr Carl Stubbings

### 2. Operating results and review of operations for the year

The loss of the Company for the half year ended 31 December 2014 amount to \$1,923,938 (December 2013: loss \$1,373,021) after providing for income tax. The key differences include launch of the PeriCoach marketing campaign with marketing expenses \$742,318 (2013: \$77,778); increased administrative expenses \$514,488 (2013: \$240,532); increased income from research and development tax incentive of \$988,107 (2013: \$520,745) as a result of increased research and development expense with the development of the PeriCoach system of \$1,538,601 (2013: \$1,103,197).

No dividend is proposed to be paid.

#### Review of operations

A review of the operations of the Company during the half year and the results of those operations are discussed as follows:

- Consumer Market Release
- Marketing Australia
  - Incontinence who wants to talk about it?
  - Serious or a toy?
  - Who do you listen to?
- Marketing US
- Marketing Europe
- Capital
- Development

## Directors' Report

31 December, 2014

**Consumer Market Release.** The past 6 months has seen the progression of the PeriCoach from controlled market release to full consumer release for Android mobiles and tablets, the latter announced on the 24th November. A controlled market release assisted the testing of systems and importantly allowed the building of our clinician network. The approval by Apple of the iOS version on the 12th of January enabled PeriCoach to be available to the bulk of smart phones and tablets. The public marketing campaign was dependant on having access to the full market, and commenced on 12 January, and sales are growing.

**Incontinence, who wants to talk about it?** Overwhelming clinical evidence supports pelvic floor exercise as the most effective non-invasive treatment of bladder leakage, and an important contributor to improvement in sexual function. These exercises, although known for nearly 70 years, are not easy. Motivation, accountability and feedback are critical success factors, with the PeriCoach as "personal coach" we expect these exercises will become more effective and patients will see a significant improvement in their pelvic floor muscles. In addition to the enormous markets of continence and sexual function, pelvic floor muscle training has also been known to assist with other significant chronic conditions such as pelvic organ prolapse (uterine and rectal), sexual dysfunction and lower back pain.

Personal recommendations optionally combined with Clinician support is the key goal of PeriCoach's marketing campaign. Bladder leakage is embarrassing and uncomfortable and to gain acceptance appropriate messaging is critical. PeriCoach aims to raise the issue of bladder leakage and sexual function in a sensitive and personal manner.

**Serious or toy?** There are a number of devices in the incontinence market which are derived from adult toys. The PeriCoach team recognises the importance continuing to build the systems strong, medical and scientific foundation. To ensure the success of PeriCoach the company has been building an expert clinician network to reinforce the credentials of the system as a serious medical device and to provide the confidence for General Practitioners and specialist women's health practitioners to recommend PeriCoach to patients.

PeriCoach's clinical advisory boards continue to validate PeriCoach as serious solution to a significant unmet medical need. The company is fortunate to have such highly credentialed members of our Australian (appointed early 2014) and US (appointed August 2014) clinical advisory boards.

To further strengthen the medical benefits of PeriCoach the company is undertaking extensive clinical trials to provide compelling independent proof of the effectiveness for incontinence and sexual function. During the last 6 months, with assistance of our clinical advisory board the company has completed the trial protocol, selected trial sites and appointed Principal Investigators. These trials are scheduled to commence February. PeriCoach will also use this data to support discussions regarding health economics and reimbursement strategies, particularly the US.

**Who do you listen to?** Our market research has shown that many women are unaware that pelvic floor health problems are so common and that something can actually be done to fix it other than "padding the problem". For many women the PeriCoach is not an insignificant purchase, and trust has to be built to support that buying decision. Behavioural studies indicates it can take up to 16 messages to support a purchasing decision.

Recommendation by a friend or respected advisor is the most sought after and trusted advice. Social media is a powerful opportunity to build that trust. The company's marketing team approached bloggers to personally use the PeriCoach. These bloggers have shared their successful experiences generating trusted messages. This is a slow process, however it builds a solid foundation. Resources of articles, expert opinion and testimonials are progressively being accumulated and deployed to increase knowledge of pelvic floor conditions to generate further messages.

Recruitment of an Australian sales team was completed in September. Their role is to build the clinicians network and raise awareness of the PeriCoach amongst General Practitioners and women's health specialists. General Practitioners are key advisers. In the busy life of a GP the efficacy credentials of the PeriCoach are critical to enable PeriCoach to be differentiated from the many pharmaceuticals and devices they see every day.

To enter the USA, world's biggest healthcare market, PeriCoach has appointed a New York specialist healthcare marketing communications agency jacobstahl Inc. jacobstahl are developing the PeriCoach global communication strategy, positioning and locating global partners. In addition jacobstahl will coordinate all PR activities in all markets.

**Analytica Limited**

**Directors' Report**

**31 December, 2014**

**Marketing US.** Analytica continues to build the foundations for the US launch. The PeriCoach has been exhibited at major clinician conferences, with strong interest and support. Again the credentials of our clinical advisory boards, lend considerable support and speaking events about the PeriCoach led by members of our CAB have attracted standing-room only attendances. The US market is very different from Australia and requires extensive preparation ensuring that all regulatory, distribution, communication and reimbursement opportunities are maximised.

**Marketing Europe.** The appointment of a Europe marketing manager is also to gain a strong understanding of the distribution, communication and reimbursement opportunities in this diverse but significant market.

**Capital.** The company received a \$989k research and development tax incentive in October. This complemented the successful placement of \$850k and the raising of \$2.56M.

**Development.** Our development team continue to design and build additional features to the PeriCoach system. These features aim to improve the patient ease-of-use, and expand the capability of the device for data collection as well as the system for data mining. Analytica is working with Australian Universities to develop several further technologies which may ensure leadership in the area of pelvic floor health. The PeriCoach has patent-pending capabilities that significantly differentiate the system from competitors. These expanded features move the PeriCoach even further ahead of competition, while expanding other market opportunities.

The momentum is building and we look forward to an exciting year.

**Auditor's independence declaration**

The auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001* for the half year ended 31 December, 2014 has been received and can be found on page 4 of the interim financial report.

This report is signed in accordance with a resolution of the Board of Directors.

Director:   
.....  
Dr Michael Monsour

Dated this 20<sup>th</sup> day of Feb 2015

**AUDITOR'S INDEPENDENCE DECLARATION  
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001  
TO THE DIRECTORS OF ANALYTICA LIMITED**

I declare that, to the best of my knowledge and belief, in relation to the review for the interim period ended 31 December 2014 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- ii. no contraventions of any applicable code of professional conduct in relation to the review.



Bentleys Brisbane Partnership  
Chartered Accountants



Stewart Douglas  
Partner

26 February 2015

**Analytica Limited**

**Interim Statement of Profit or Loss and Other Comprehensive Income  
For the Half Year Ended 31 December, 2014**

		31 December 2014	31 December 2013
	Note	\$	\$
Sales revenue		4,859	-
Cost of sales		(6,766)	-
Gross profit		<u>(1,907)</u>	-
Operating grants		988,107	520,745
Interest revenue		14,894	6,939
Other income		4,752	1,442
Administrative expenses	2	(514,488)	(240,532)
Depreciation, amortisation and impairments	2	(47,308)	(8,060)
Fair value adjustment		(24,026)	54,325
Finance costs		(290)	(3,086)
Marketing expenses	2	(742,318)	(77,778)
Occupancy costs		(3,760)	(2,915)
Option expenses		-	(407,037)
Patent maintenance	2	(47,806)	(113,867)
Research and development	2	(1,538,601)	(1,103,197)
Loss on exchange differences		<u>(11,187)</u>	-
<b>Profit before income tax</b>		<b>(1,923,938)</b>	<b>(1,373,021)</b>
Income tax expense		-	-
<b>Profit for the half year</b>		<b><u>(1,923,938)</u></b>	<b><u>(1,373,021)</u></b>
<b>Other comprehensive income, net of income tax</b>			
<b>Items that will not be reclassified subsequently to profit or loss</b>		-	-
<b>Items that will be reclassified to profit or loss when specific conditions are met</b>		-	-
<b>Total comprehensive income for the half year</b>		<b><u>(1,923,938)</u></b>	<b><u>(1,373,021)</u></b>
Earnings per share			
Basic/diluted earnings per share (cents)		(0.21)	(0.23)

The accompanying notes form part of these financial statements.



**Analytica Limited**

**Interim Statement of Financial Position**

**As At 31 December, 2014**

	31 December 2014	30 June 2014
Note	\$	\$
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	3,426,209	1,957,868
Trade and other receivables	37,225	36,652
Inventories	531,128	177,170
Prepayments	220,528	381,638
<b>TOTAL CURRENT ASSETS</b>	<b>4,215,090</b>	<b>2,553,328</b>
<b>NON-CURRENT ASSETS</b>		
Other financial assets	49,101	73,130
Property, plant and equipment	50,052	21,647
Intangible assets	140,372	176,816
<b>TOTAL NON-CURRENT ASSETS</b>	<b>239,525</b>	<b>271,593</b>
<b>TOTAL ASSETS</b>	<b>4,454,615</b>	<b>2,824,921</b>
<b>LIABILITIES</b>		
<b>CURRENT LIABILITIES</b>		
Trade and other payables	475,390	279,679
Borrowings	907	10,342
Short-term provisions	27,786	42,755
Employee benefits	99,789	86,841
<b>TOTAL CURRENT LIABILITIES</b>	<b>603,872</b>	<b>419,617</b>
<b>NON-CURRENT LIABILITIES</b>		
Employee benefits	39,045	30,782
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>39,045</b>	<b>30,782</b>
<b>TOTAL LIABILITIES</b>	<b>642,917</b>	<b>450,399</b>
<b>NET ASSETS</b>	<b>3,811,698</b>	<b>2,374,522</b>
<b>EQUITY</b>		
Issued capital	4 92,153,762	88,792,648
Reserves	534,737	534,737
Retained earnings	(88,876,801)	(86,952,863)
<b>TOTAL EQUITY</b>	<b>3,811,698</b>	<b>2,374,522</b>

The accompanying notes form part of these financial statements.

**Analytica Limited**

**Interim Statement of Changes in Equity**

**For the Half Year Ended 31 December, 2014**

**Half Year Ended 31 December 2014**

	Ordinary Shares	Retained Earnings	Option Reserve	Total
Note	\$	\$	\$	\$
<b>Balance at 1 July 2014</b>	<b>88,792,648</b>	<b>(86,952,863)</b>	<b>534,737</b>	<b>2,374,522</b>
Profit (loss) attributable to members of the entity	-	(1,923,938)	-	(1,923,938)
Shares issued during the year	3,715,760	-	-	3,715,760
Transaction costs	(354,528)	-	-	(354,528)
Shareholder refunds	(118)	-	-	(118)
<b>Balance at 31 December, 2014</b>	<b>92,153,762</b>	<b>(88,876,801)</b>	<b>534,737</b>	<b>3,811,698</b>

**Half Year Ended 31 December 2013**

	Ordinary Shares	Retained Earnings	Option Reserve	Total
Note	\$	\$	\$	\$
<b>Balance at 1 July 2013</b>	<b>83,943,597</b>	<b>(83,776,854)</b>	<b>-</b>	<b>166,743</b>
Profit (loss) attributable to members of the entity	-	(1,373,021)	-	(1,373,021)
Shares issued during the year	2,200,000	-	-	2,200,000
Transaction costs	(142,974)	-	-	(142,974)
<b>Transactions with owners in their capacity as owners</b>				
Share based payment transactions	-	-	407,037	407,037
<b>Balance at 31 December, 2013</b>	<b>86,000,623</b>	<b>(85,149,875)</b>	<b>407,037</b>	<b>1,257,785</b>

The accompanying notes form part of these financial statements.

**Analytica Limited**

**Interim Statement of Cash Flows**  
**For the Half Year Ended 31 December, 2014**

	31 December 2014	31 December 2013
Note	\$	\$
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Receipts from customers	4,465	-
Receipts from grants	989,982	520,745
Other receipts	4,946	1,442
Interest received	14,894	6,939
Payments to suppliers and employees	(2,879,109)	(1,503,955)
Finance costs	(290)	(3,086)
Net cash provided by/(used in) operating activities	<u>(1,865,112)</u>	<u>(977,915)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of property, plant and equipment	(42,102)	(3,973)
Net cash used by investing activities	<u>(42,102)</u>	<u>(3,973)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from issue of shares	3,713,722	2,200,000
Payment of transaction costs	(328,733)	(142,974)
Net cash used by financing activities	<u>3,384,989</u>	<u>2,057,026</u>
Net increase/(decrease) in cash and cash equivalents held	1,477,775	1,075,138
Cash and cash equivalents at beginning of year	1,947,526	349,416
Cash and cash equivalents at end of the half year	<u>3,425,301</u>	<u>1,424,554</u>

The accompanying notes form part of these financial statements.

## Analytica Limited

# Summary of Significant Accounting Policies

For the Half Year Ended 31 December, 2014

### 1 Summary of Significant Accounting Policies

This condensed interim financial report for the reporting period ending 31 December, 2014 has been prepared in accordance with the requirements of the *Corporations Act 2001* and Australian Accounting Standard AASB 134: *Interim Financial Reporting*.

The interim financial report is intended to provide users with an update on the latest annual financial statements of Analytica Limited. As such it does not contain information that represents relatively insignificant changes occurring during the half year within Analytica Limited. This condensed financial report does not include all the notes normally included in an annual financial report. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of Analytica Limited for the year ended 30 June 2014, together with any public announcements made during the half year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

The financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

Significant accounting policies adopted in the preparation of these financial statements are presented below and are consistent with prior reporting periods unless otherwise stated.

The interim financial report covers Analytica Limited as an individual entity. Analytica Limited is a for-profit Company limited by shares, incorporated and domiciled in Australia.

The functional and presentation currency of Analytica Limited is Australian dollars.

The financial report was authorised for issue by the Directors on the date the Directors report was signed.

Comparatives are consistent with prior years, unless otherwise stated.

#### (a) Revenue and other income

Revenue is recognised when the amount of the revenue can be measured reliably, it is probable that economic benefits associated with the transaction will flow to the Company and specific criteria relating to the type of revenue as noted below, has been satisfied.

Revenue is measured at the fair value of the consideration received or receivable and is presented net of returns, discounts and rebates.

#### Other income

Other income is recognised on an accruals basis when the Company is entitled to it.

#### (b) Inventories

Inventories are measured at the lower of cost and net realisable value. Cost of inventory is determined using the first-in-first-out basis and is net of any rebates and discounts received.

## **Summary of Significant Accounting Policies**

**For the Half Year Ended 31 December, 2014**

**(c) Property, Plant and Equipment**

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment of losses.

**Depreciation**

Property, plant and equipment, excluding freehold land, is depreciated on a straight-line basis over the assets useful life to the Company, commencing when the asset is ready for use.

Leased assets and leasehold improvements are amortised over the shorter of either the unexpired period of the lease or their estimated useful life.

**(d) Cash and cash equivalents**

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

Bank overdrafts also form part of cash equivalents for the purpose of the interim statement of cash flows and are presented within current liabilities on the interim statement of financial position.

**(e) Going concern**

The financial statements have been prepared on a going concern basis.

This basis has been adopted as the company has sufficient cash at 31 December 2014 to conduct its affairs. The company has a guarantee of continuing financial support from Dr Monsour to allow the company to meet its liabilities and it is the belief that such financial support will continue to be made available.

The company's forward cash flow projections currently indicate that the company will be required to raise additional funds to meet forecast needs. The Directors have considered this position and have assessed available funding options and believe should funding be required that sufficient funds could be sourced to satisfy creditors as and when they fall due.

The company also expects to generate increased sales income during the remainder of the 2015 year from the sales of its PeriCoach.

However, if adequate capital raising is not achieved the company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might be necessary should the company not continue as a going concern.

**(f) Adoption of new and revised accounting standards**

The company has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Any significant impact on the accounting principles of the company from the adoption of these Accounting Standards and Interpretations are disclosed in the relevant accounting policy. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Company.

**Notes to the Financial Statements**  
**For the Half Year Ended 31 December, 2014**

**2 Result for the Half Year**

	31 December 2014 \$	31 December 2013 \$
The following revenue and expense items are relevant in explaining the financial performance for the interim period:		
Sale of goods	4,859	-
Operating grants	988,107	520,745
Interest received	14,894	6,939
Royalties	4,946	1,442
Loss on disposal of assets	(194)	-
	<b>1,012,612</b>	<b>529,126</b>
<b>Administration</b>		
Administration - general	31,993	17,531
Compliance costs	272,333	169,465
Employee costs	210,163	53,536
	<b>514,489</b>	<b>240,532</b>
<b>Marketing costs</b>		
PeriCoach	416,584	57,703
Wages	325,734	20,075
	<b>742,318</b>	<b>77,778</b>
<b>Depreciation and amortisation</b>		
Property plant and equipment	10,864	4,727
Intangible assets	36,444	3,333
	<b>47,308</b>	<b>8,060</b>
<b>Research and development</b>		
Auto Start Burette	8,731	-
PeriCoach	1,216,320	742,229
Employee and labour	286,822	323,595
Other	26,727	37,373
	<b>1,538,600</b>	<b>1,103,197</b>
<b>Patent maintenance</b>		
ELF 2	230	5,010
AutoStart Burette	22,799	44,452
PeriCoach	24,777	64,405
	<b>47,806</b>	<b>113,867</b>

## Notes to the Financial Statements

### For the Half Year Ended 31 December, 2014

#### 3 Operating Segments

##### Types of products and services by reportable segment

###### (i) Medical Devices

- AutoStart Burette
- Perineometer
- ELF 2

Analytica's lead product is the Perineometer device branded PeriCoach, to assist women and their clinicians in treatment of Stress Urinary Incontinence. The PeriCoach entered controlled market release in June 2014, with clinical trials undertaken in November 2014, with its public release in January 2015.

Analytica is also commercialising the AutoStart Burette infusion system. The AutoStart Burette set automatically restarts the delivery of intravenous fluid once the burette has dispensed its predetermined amount of liquid or drug. Automatic restart of the IV fluid, once the drug is dispensed can provide enormous savings in nursing time during and following a medication event, and reduces the risk of blood clots forming that may obstruct the intravenous canula.

Analytica has licensed the AutoStart Burette and other burette intellectual property to Medical Australia (Formerly BMDI Tuta) for distribution in the Australian Market. The AutoStart Burette has a TGA ARTG entry, CE-marking, and USFDA 510(k) 'approval'. Distribution agreement has been signed with Taiwan Allied Dragon who are negotiating registration of the AutoStart Burette in Taiwan.

Analytica continues the development of this medical device for treatment of muscular spasticity. The ELF2 device delivers a low-frequency voltage used by neurologists to locate nerve endings during Botulinum neurotoxin A injection treatment. Analytica's development of this device, licenced from Gorman ProMed Ltd in 2012, is to enhance usability features of a device currently in use and respected by the market. The device is scheduled for release in 2015.

###### (ii) Corporate

The corporate segment includes all other operations including the administration, and associated listed public company expenditure.

##### Basis of accounting for purposes of reporting by operating segments

###### (a) Accounting policies adopted

Unless stated below, all amounts reported to the Board of Directors, being the chief operating decision maker with respect to operating segments, are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of Analytica Limited.

###### (b) Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that receives the majority of economic value from the asset. In the majority of instances, segment assets are clearly identifiable on the basis of their nature and physical location.

## Analytica Limited

### Notes to the Financial Statements For the Half Year Ended 31 December, 2014

#### (c) Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to Analytica Limited as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

#### (d) Segment performance

	Medical Devices		Corporate		Total	
	31 December	31 December	31 December	31 December	31 December	31 December
	2014	2013	2014	2013	2014	2013
	\$	\$	\$	\$	\$	\$
<b>REVENUE</b>						
Revenue from external customers	4,859	-	-	-	4,859	-
Grant revenue	-	-	988,107	520,745	988,107	520,745
Royalties	4,946	1,442	-	-	4,946	1,442
Loss on disposal of asset	-	-	(194)	-	(194)	-
Interest revenue	-	-	14,894	6,939	14,894	6,939
<b>Total segment revenue</b>	<b>9,805</b>	<b>1,442</b>	<b>1,002,807</b>	<b>527,684</b>	<b>1,012,612</b>	<b>529,126</b>
Depreciation and amortisation	(38,728)	(3,333)	(8,580)	(4,727)	(47,308)	(8,060)
Cost of sales	(6,766)	-	-	-	(6,766)	-
Interest expense	-	-	(290)	(3,086)	(290)	(3,086)
Marketing	(742,318)	(77,778)	-	-	(742,318)	(77,778)
Other expense	-	-	(553,461)	(596,159)	(553,461)	(596,159)
Patent maintenance	(47,806)	(113,867)	-	-	(47,806)	(113,867)
Research and development	(1,538,601)	(1,103,197)	-	-	(1,538,601)	(1,103,197)
<b>Total segment expense</b>	<b>(2,374,219)</b>	<b>(1,298,175)</b>	<b>(562,331)</b>	<b>(603,972)</b>	<b>(2,936,550)</b>	<b>(1,902,147)</b>
<b>Segment operating profit (loss)</b>	<b>(2,364,414)</b>	<b>(1,296,733)</b>	<b>440,476</b>	<b>(76,288)</b>	<b>(1,923,938)</b>	<b>(1,373,021)</b>

#### (e) Segment assets

<b>Segment assets</b>	<b>140,372</b>	<b>8,941</b>	<b>4,265,142</b>	<b>1,455,532</b>	<b>4,405,514</b>	<b>1,464,473</b>
<b>Financial assets at fair value through profit and loss</b>	<b>-</b>	<b>-</b>	<b>49,101</b>	<b>87,756</b>	<b>49,101</b>	<b>87,756</b>
	<b>140,372</b>	<b>8,941</b>	<b>4,314,243</b>	<b>1,543,288</b>	<b>4,454,615</b>	<b>1,552,229</b>

#### (f) Segment liabilities

<b>Segment liabilities</b>	<b>-</b>	<b>-</b>	<b>(642,917)</b>	<b>(294,444)</b>	<b>(642,917)</b>	<b>(294,444)</b>
----------------------------	----------	----------	------------------	------------------	------------------	------------------



## Analytica Limited

### Notes to the Financial Statements For the Half Year Ended 31 December, 2014

#### 4 Issued Capital

	31 December 2014	30 June 2014
	\$	\$
Ordinary shares: 939,220,439 (June 2014: 815,361,809)	92,153,762	88,792,648
Unlisted options: 53,850,000 (June 2014: 53,850,000)	-	-

##### (a) Ordinary shares

	31 December 2014	30 June 2014
	No.	No.
At the beginning of the reporting period	815,361,809	559,988,815
Shares issued during the year		
11 November 2013	-	129,411,623
23 April 2014	-	75,000,000
22 May 2014	-	34,627,433
22 May 2014	-	16,333,938
8 October 2014	28,333,334	-
5 November 2014	85,540,964	-
5 November 2014	9,984,332	-
At the end of the reporting period	<u>939,220,439</u>	<u>815,361,809</u>

Analytica Limited issued the following fully paid ordinary shares to raise capital for marketing costs in connection with the launch of the PeriCoach System, and working capital expenses:

On 8 October 2014 Analytica allotted 28,333,334 fully paid ordinary shares at \$0.03 per share.

On 5 November 2014 Analytica allotted 85,540,964 fully paid ordinary shares at \$0.03 per share as a result of its 1 for 8 entitlement offer.

On 5 November 2014 Analytica privately placed a further 9,984,332 fully paid ordinary shares at \$0.03 per share.

#### 5 Contingencies

In the opinion of the Directors, the Company did not have any contingencies at 31 December, 2014 (31 December 2013: None).

## **Analytica Limited**

### **Notes to the Financial Statements For the Half Year Ended 31 December, 2014**

#### **6 Related Parties**

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

The following transactions occurred with related parties:

- i) During the half year accounting services were provided to the Company by Avance Chartered Accountants, a firm which director Mr Ross Mangelsdorf is a partner. Fees of \$71,400 (December 2013 \$21,000) were charged for these services to 31 December.
- ii) Director provision of (unsecured) loan facility to the Company up to \$400,000 provided by MPAMM Pty Ltd, a related entity associated with Dr. Monsour. Facility 100% unused at reporting date, (June 2014: 100% unused).

#### **7 Events Occurring After the Reporting Date**

No matters or circumstances have arisen since the end of the half year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.


**Analytica Limited**

**Directors' Declaration**

The directors of the Company declare that:

1. The interim financial statements and notes, as set out on pages 5 to 15 are in accordance with the *Corporations Act 2001*, including:
  - (a) complying with Accounting Standard AASB 134: Interim Financial Reporting; and
  - (b) give a true and fair view of the Company's financial position as at 31 December, 2014 and of its performance for the half-year ended on that date.
2. In the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director  .....  
Dr Michael Monsour

Dated this 26<sup>th</sup> day of FEB 2015

**ANALYTICA LIMITED**  
**ABN 12 006 464 866**

**INDEPENDENT REVIEW REPORT  
TO THE MEMBERS OF ANALYTICA LIMITED**

**Report on the Half-year Financial Report**

We have reviewed the accompanying half-year financial report of Analytica Limited (“the company”), which comprises the condensed statement of financial position as at 31 December 2014 and condensed statement of comprehensive income, condensed statement of changes in equity and condensed statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information and the directors’ declaration of the company.

**Directors Responsibility for the Half-year Financial Report**

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

**Auditors Responsibility**

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of an Interim Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the company's financial position as at 31 December 2014 and its performance for the interim period ended on that date; and complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As auditor of Analytica Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

### Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Analytica Limited is not in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the company's financial position as at 31 December 2014 and of its performance for the half-year period ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

### Emphasis of Matter

Without modifying our opinion, we draw attention to Note 1 in the financial report which indicates that the company will be required to generate sales revenue or raise additional funds to meet forecast cash needs. These conditions, along with other matters as set forth in Note 1, indicate the existence of a material uncertainty that may cast significant doubt about the ability to continue as a going concern and therefore, the company may be unable to realise its assets and discharge its liabilities in the normal course of business.



Bentleys Brisbane Partnership  
Chartered Accountants



Stewart Douglas  
Partner

26 February 2015